Implementation of extended prolonged venous thromboembolism prophylaxis with rivaroxaban after major abdominal and pelvic surgery safety and early outcomes.

Abstract

Purpose: Venous thromboembolism (VTE) after colorectal surgery is a well-documented complication, resulting in a general recommendation of extended post discharge prophylaxis. Rivaroxaban, a factor Xa inhibitor, is a daily tablet approved for treatment of VTE and prophylaxis after orthopedic surgery. The purpose of this study is to evaluate the safety of rivaroxaban for extended prophylaxis after major abdominal and pelvic surgery. Methods: This is a retrospective review of patients undergoing major colorectal surgery at a regional hospital in Kiev, Ukraine. Patients received peri-operative VTE prophylaxis with subcutaneous heparin and then transitioned to rivaroxaban for a total of 30 days. Occurrences of major or minor bleeding, blood transfusion, and a need for re-intervention were noted. Phone surveys were administered on post-operative day 30 to assess compliance and satisfaction with the regimen. Results A total of 51 patients were included in the study with an average age of 62.4 years old. Seventy-one percent of the cases were abdominal cases, 29% were pelvic cases and 59% were done laparoscopically. There was one episode of major intra-abdominal bleeding requiring return to the operating room. There were 2 minor bleeding episodes not requiring intervention. There were no VTE events in the group. The phone survey response rate was 100%. All but one patient reported completing the full course of rivaroxaban. Patients reported that oral prophylaxis was easy to adhere to and preferable compared to injections. Conclusion Implementation of extended prophylaxis with rivaroxaban is easy, safe and does not increase rates of post-operative bleeding.

Use of direct oral anticoagulants for postoperative venous thromboembolism prophylaxis after surgery for gynecologic malignancies

“…25 A Ukranian retrospective cohort study by Tyselskyi et al evaluated the safety of 10 mg rivaroxaban taken once a day following major colorectal surgery for 30 days. 27 In this study, 41.2% of surgeries were laparotomies while 58.8% were laparoscopic surgeries . 27 A pre-existing malignancy was the indication for 90% of these surgeries.…”

“…27 In this study, 41.2% of surgeries were laparotomies while 58.8% were laparoscopic surgeries . 27 A pre-existing malignancy was the indication for 90% of these surgeries. By day 3 after surgery, all patients were transitioned from postoperative low molecular weight heparin to rivaroxaban, once they were able to tolerate a regular diet and were hemoglobin stable.…”

“…27 There were no venous thromboembolisms recorded within 30 days. 27 The result from this study supported the safety and efficacy of on February 20, 2022 by guest. Protected by copyright.…”

“…By day 3 after surgery, all patients were transitioned from postoperative low molecular weight heparin to rivaroxaban, once they were able to tolerate a regular diet and were hemoglobin stable. 27 Three of 51 patients developed bleeding complications; 1 of these 3 patients returned to the operating theater. 27 There were no venous thromboembolisms recorded within 30 days.…”

“…27 Three of 51 patients developed bleeding complications; 1 of these 3 patients returned to the operating theater. 27 There were no venous thromboembolisms recorded within 30 days. 27 The result from this study supported the safety and efficacy of on February 20, 2022 by guest.…”